Vistagen Announces Results From Exploratory Phase 2A Study Of PH80 In Women Diagnosed With Menopausal Hot Flashes
Portfolio Pulse from Benzinga Newsdesk
Vistagen announces positive results from an exploratory Phase 2A study of PH80 nasal spray in women diagnosed with menopausal hot flashes. The study showed statistically significant efficacy versus placebo, with PH80 being safe and well-tolerated.
June 07, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen's PH80 nasal spray demonstrates significant efficacy in treating menopausal hot flashes in a Phase 2A study, potentially improving the treatment landscape for women worldwide.
The positive results from the Phase 2A study of PH80 indicate that the product has potential to be a successful treatment for menopausal hot flashes. This could lead to increased demand for the product and, in turn, boost Vistagen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100